Johnson & Johnson agrees to acquire Ambrx Biopharma for $2bn

Johnson & Johnson (J&J) has signed a definitive agreement for the acquisition of Ambrx Biopharma in a cash deal valued at $2bn.

Jan 9, 2024 - 18:00

Johnson & Johnson agrees to acquire Ambrx Biopharma for $2bn

Johnson & Johnson (J&J) has signed a definitive agreement for the acquisition of Ambrx Biopharma in a cash deal valued at $2bn.

Read the original article

Tags:

Previous Article

EC approves Pfizer’s Talzenna combo for prostate cancer treatment

HH-006 by Huahui Health for Hepatitis D: Likelihood of Approval

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

23andMe breach targeted Chinese, Jewish populations

23andMe breach targeted Chinese, Jewish populations

Jan 30, 2024

STAT+: Pharmalittle: We’re reading about White House eyeing PBMs, Pfizer CEO’s frustrations, and more

STAT+: Pharmalittle: We’re reading about White House ey...

Feb 29, 2024

Cost of disease-modifying therapies for multiple sclerosis continues to rise in US

Cost of disease-modifying therapies for multiple sclero...

May 20, 2023